JP2017514801A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514801A5
JP2017514801A5 JP2016561311A JP2016561311A JP2017514801A5 JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5 JP 2016561311 A JP2016561311 A JP 2016561311A JP 2016561311 A JP2016561311 A JP 2016561311A JP 2017514801 A5 JP2017514801 A5 JP 2017514801A5
Authority
JP
Japan
Prior art keywords
xaa
chem
glu
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514801A (ja
JP6768515B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/057442 external-priority patent/WO2015155151A1/en
Publication of JP2017514801A publication Critical patent/JP2017514801A/ja
Publication of JP2017514801A5 publication Critical patent/JP2017514801A5/ja
Application granted granted Critical
Publication of JP6768515B2 publication Critical patent/JP6768515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561311A 2014-04-07 2015-04-07 二重アシル化glp−1化合物 Active JP6768515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163697.7 2014-04-07
EP14163697 2014-04-07
PCT/EP2015/057442 WO2015155151A1 (en) 2014-04-07 2015-04-07 Double-acylated glp-1 compounds

Publications (3)

Publication Number Publication Date
JP2017514801A JP2017514801A (ja) 2017-06-08
JP2017514801A5 true JP2017514801A5 (enExample) 2018-05-10
JP6768515B2 JP6768515B2 (ja) 2020-10-14

Family

ID=50434120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016561311A Active JP6768515B2 (ja) 2014-04-07 2015-04-07 二重アシル化glp−1化合物

Country Status (6)

Country Link
US (1) US10689429B2 (enExample)
EP (1) EP3129041B1 (enExample)
JP (1) JP6768515B2 (enExample)
CN (1) CN106132985B (enExample)
ES (1) ES2741507T3 (enExample)
WO (1) WO2015155151A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
EP3423481B1 (en) 2016-03-03 2020-10-07 Novo Nordisk A/S Glp-1 derivatives and uses thereof
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
MA53076B1 (fr) * 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
WO2019200594A1 (zh) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
IL320142A (en) 2018-10-11 2025-06-01 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use
CN111378027B (zh) * 2018-12-29 2022-04-15 万新医药科技(苏州)有限公司 一种索玛鲁肽前体的制备方法
CN114340655A (zh) * 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法
MX2022004779A (es) 2019-11-06 2022-06-14 Novo Nordisk As Agonistas del receptor del péptido 1 similar al glucagón (glp-1) en demencia.
JP2023502004A (ja) 2019-11-07 2023-01-20 ノヴォ ノルディスク アー/エス Glp-1作動薬、sglt2阻害剤、およびn-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩を含む固形組成物
US20230093542A1 (en) 2020-02-18 2023-03-23 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP7777085B2 (ja) 2020-04-29 2025-11-27 ノヴォ ノルディスク アー/エス Glp-1作動薬およびヒスチジンを含む固形組成物
CA3194956A1 (en) 2020-09-11 2022-03-17 Glympse Bio, Inc. Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
CN116848243B (zh) 2022-03-30 2024-03-19 北京质肽生物医药科技有限公司 多肽缀合物的液体药物组合物和其使用方法
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
WO2001035988A1 (en) 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
JPWO2004037859A1 (ja) * 2002-10-11 2006-02-23 株式会社三和化学研究所 Glp−1誘導体及びその経粘膜吸収型製剤
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー/エス A−b−c−d−で誘導体化されたペプチドとその治療用途
JP5411366B2 (ja) * 2009-12-16 2014-02-12 ノヴォ ノルディスク アー/エス 二重アシル化glp−1誘導体
EP2637698B1 (en) * 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2012098188A1 (en) * 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 particles and compositions
HUE031405T2 (en) 2011-04-12 2017-07-28 Novo Nordisk As Double-acylated GLP-1 derivatives
JP6126097B2 (ja) * 2011-09-06 2017-05-10 ノヴォ ノルディスク アー/エス Glp−1誘導体
WO2013167455A1 (en) * 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
WO2013167454A1 (en) * 2012-05-08 2013-11-14 Novo Nordisk A/S Double-acylated glp-1 derivatives
HK1217443A1 (zh) * 2013-01-29 2017-01-13 奥莎迪药品管理有限公司 用於糖尿病的口服治疗的药物组合物

Similar Documents

Publication Publication Date Title
JP2017514801A5 (enExample)
JP2014529629A5 (enExample)
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
JP2015517478A5 (enExample)
JP2015517477A5 (enExample)
JP2010538049A5 (enExample)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
TWI362392B (en) Acylated glp-1 compounds
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP5755398B2 (ja) 伸長されたglp−1化合物
JP2008533105A5 (enExample)
CN104519902B (zh) 双酰化glp‑1衍生物
JP2018505146A5 (enExample)
JP2012529463A5 (enExample)
JP2010529004A5 (enExample)
WO2011080102A3 (en) Glp-1 analogues and derivatives
JP2012506402A5 (enExample)
JP2024059696A (ja) 5.8~8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液
NZ597554A (en) Selective glucagon-like-peptide-2 (glp-2) analogues
JP2017528419A5 (enExample)
JP2019513126A5 (enExample)
JP2016531110A5 (enExample)
JP2017508741A5 (enExample)
RU2020109881A (ru) Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита